Core Insights - iRhythm Technologies has formed a strategic partnership with Lucem Health to enhance early detection of undiagnosed arrhythmias in high-risk patient populations [1][2][3] - The collaboration aims to shift from reactive to proactive healthcare, utilizing AI to identify arrhythmia risks before symptoms manifest [2][3] - The partnership targets over 27 million individuals in the U.S. who could benefit from proactive cardiac monitoring [2][8] Company Overview - iRhythm Technologies is a digital health leader focused on solutions that detect, predict, and prevent disease, utilizing wearable biosensors and cloud-based analytics [18] - Lucem Health specializes in AI-driven early disease detection, aiming to improve clinical outcomes and resource allocation in healthcare [19] Partnership Details - The collaboration will leverage Lucem Health's AI platform and iRhythm's diagnostic services to enable earlier identification of arrhythmia risks [2][3] - The first commercial offering will focus on patients with conditions like Type 2 diabetes, chronic kidney disease, chronic obstructive pulmonary disease, and coronary artery disease [4][6] Clinical Impact - Early pilot testing indicates improved targeting of patient populations at risk for arrhythmias, facilitating earlier clinical engagement [7] - The predictive AI solution is expected to enhance arrhythmia detection among an estimated 27 million undiagnosed patients in the U.S., potentially reducing healthcare resource utilization and costs [8][15] Economic Considerations - Cardiac arrhythmias affect approximately 1 in 20 U.S. adults, and untreated cases can lead to severe health complications, emphasizing the need for early detection [9][11] - Research shows that patients with arrhythmias incur significantly higher healthcare costs, reinforcing the economic case for earlier detection and intervention [13][14]

FREMONT, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (Nasdaq: ENVX, ENVXW) (“Enovix”), a global high-performance battery company, announced that it posted on its website here a letter to shareholders from President and CEO, Dr. Raj Talluri, and CFO, Ryan Benton, discussing the company’s second quarter 2025 results. The company will host a live webcast at 5:00 PM ET / 2:00 PM PT to discuss the results and provide business updates. To register for the webcast, please visit: https://enovix-q2- ...

GUANGZHOU, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- YSX TECH. CO., LTD (the “Company,” “our,” “us” or “YSXT”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced its financial results for the fiscal year ended March 31, 2025. Key Financial Metrics for Fiscal Year 2025 Total revenue grew by approximately 22.0% to approximately $71.5 million in the fiscal year ...

Second Quarter Results Total revenues of $36.5 million, a 23% year-over-year improvementNet income of $0.9 million and diluted earnings per share of $0.34, which includes a positive impact of $1.4 million related to the release of our deferred tax valuation allowance in CanadaAdjusted EBITDA of $2.2 million, a $1.3 million year-over-year improvement $25.4 million in cash and $7.7 million of total debt as of June 30, 2025 HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (Nasdaq: NCSM) ...

WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. T ...

Core Insights - Stryker reported a consolidated net sales of $6.0 billion for Q2 2025, reflecting an 11.1% increase compared to the previous year, with organic net sales growing by 10.2% [2][14][24] - The company experienced strong growth in its MedSurg and Neurotechnology segments, with net sales increasing by 17.3% to $3.8 billion, while Orthopaedics saw a modest growth of 2.0% to $2.2 billion [2][3][24] - Adjusted net earnings for the quarter reached $1.2 billion, marking an 11.6% increase, with adjusted earnings per diluted share rising to $3.13, up 11.4% [4][14][24] Sales Performance - Total net sales growth was driven by a combination of increased unit volume and higher prices, with organic net sales growth of 10.2% attributed to 9.7% from unit volume and 0.5% from price increases [2][24] - MedSurg and Neurotechnology segment's organic net sales increased by 11.0%, while Orthopaedics' organic net sales grew by 9.0% [2][3][24] - The U.S. market contributed significantly, with reported sales of $4.6 billion, reflecting a 12.5% increase, while international sales grew by 6.8% [24][28] Earnings Analysis - Reported net earnings for the quarter were $884 million, a 7.2% increase, with a diluted earnings per share of $2.29, up 7.0% [4][14][24] - Adjusted gross profit margin was reported at 65.4%, while adjusted operating income margin increased to 25.7%, up 110 basis points [4][14][24] - The company raised its full-year 2025 guidance, expecting organic net sales growth of 9.5% to 10.0% and adjusted net earnings per diluted share in the range of $13.40 to $13.60 [5][6] Market Outlook - Stryker anticipates a modestly favorable pricing impact and a slight positive effect from foreign exchange rates on sales and adjusted net earnings per diluted share [6][7] - The estimated net impact from tariffs in 2025 is approximately $175 million, reflecting recent updates in trade policies [7]

SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 21, 2025, after the market closes. A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.com. A replay will be available approximately two hours after the conclusion of the live event. About ZoomZoom’s mission is t ...

Company Overview - Synergy CHC Corp. is a fast-growing consumer health and wellness company, providing products aimed at improving health and wellness [3] Upcoming Financial Results - The company plans to release its financial results for the second quarter ended June 30, 2025, on August 14, 2025, before market trading opens [1] - A conference call will be held at 9:00 a.m. ET / 6:00 a.m. PT with CEO Jack Ross and CFO Jaime Fickett to discuss the results [2] Product Portfolio - Synergy's brand portfolio includes FOCUSfactor, a clinically studied brain health supplement that enhances memory, concentration, and focus, and Flat Tummy, a lifestyle brand focused on women's wellness and weight management [3]

Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the Phase 3 Aspire study evaluating GTX-102 (apazunersen) as a treatment for Angelman Syndrome is fully enrolled, with approximately 129 participants ages four to 17 with a genetically confirmed diagnosis of full m ...

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Partici ...